Eglonyl solution 50mg/ml 2ml ampoules, 6pcs

Composition

1 ampoule (2 ml) contains:

Active ingredient:

sulpiride 100 mg;

excipients:

sulfuric acid,

sodium chloride,

water d /

i Pharmacological action

Eglonyl is an atypical antipsychotic from the group of substituted benzamides. It has moderate neuroleptic activity in combination with stimulating and thymoanaleptic (antidepressant) effects.

The neuroleptic effect is associated with an anti-dopaminergic effect. In the central nervous system, sulpiride mainly blocks dopaminergic receptors of the limbic system, but it has little effect on the neostriatic system, it has an antipsychotic effect. The peripheral effect of sulpiride is based on the inhibition of presynaptic receptors. An increase in the amount of dopamine in the central nervous system is associated with an improvement in mood, with a decrease in the development of symptoms of depression.

The antipsychotic effect of sulpiride is manifested in doses of more than 600 mg / day, in doses up to 600 mg/day, the stimulating and antidepressant effects predominate.

Eglonyl has no significant effect on adrenergic, cholinergic, serotonin, histamine and GABA receptors.

In small doses, Eglonyl can be used as an additional tool in the treatment of psychosomatic diseases, in particular, it is effective in relieving the negative mental symptoms of gastric and duodenal ulcers. In irritable bowel syndrome, sulpiride reduces the intensity of abdominal pain and leads to an improvement in the patient’s clinical condition.

Low doses of sulpiride (50-300 mg / day) are effective for dizziness, regardless of the etiology. Sulpiride stimulates prolactin secretion and has a central antiemetic effect (inhibition of the emetic center) due to the blockade of dopamine D2 receptors of the trigger zone of the emetic center.

Indications

As monotherapy or in combination with other psychotropic drugs:

• acute and chronic schizophrenia;
• acute delirious states;
• depressions of various etiologies

Contraindications

• hypersensitivity to sulpiride or other components of the drug.
• prolactin-dependent tumors (e. g. prolactinoma of the pituitary gland and breast cancer);
• hyperprolactinemia;
• acute intoxication with ethanol, hypnotics, opioid analgesics;
• mood disorders, aggressive behavior, manic psychosis;
• pheochromocytoma;
• lactation;
• children up to age 18 years (for tablets and solution for the/m introduction);
• children up to age 6 years (for capsules);
• in combination with sultopride, a dopaminergic receptor agonists (amantadine, apomorphine, bromocriptine, cabergoline, entacapone, lisuride, ropinirol, piribedil, pramipexole, quinagolide, ropinirole);

Due to the presence of lactose in the drug, it is contraindicated in congenital galactosemia, glucose/galactose malabsorption syndrome or lactase deficiency.

With caution: It is not recommended to prescribe Eglonyl to pregnant women, except in cases when the doctor, after assessing the ratio of benefits and risks for the pregnant woman and the fetus, decides that the use of the drug is necessary.

It recommended the appointment of sulpiride in combination with ethanol, and levodopa, drugs that can cause ventricular arrhythmia type “torsade de pointes” (antiarrhythmic agents of class 1 a (quinidine, gedragingen, disopyramide) and class III (amiodarone, sotalol, dofetilide, ibutilide)), some neuroleptics (thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, amisulpride, tiapride, pimozide, haloperidol, droperidol) and other drugs, such as: bepridil, cisapride have diphemanil, intravenous erythromycin, mizolastine, intravenous vincamine has, halofantrine, pentamidine, sparfloxacin, moxifloxacin, etc.

Precautions should be taken when prescribing Eglonyl to patients with renal and/or hepatic insufficiency, a history of neuroleptic malignant syndrome, a history of epilepsy or convulsive seizures, severe heart disease, arterial hypertension, patients with Parkinsonism, dysmenorrhea, and the elderly

Side effects

From the endocrine system: reversible hyperprolactinemia may develop, the most common manifestations of which are galactorrhea, amenorrhea, menstrual disorders, less often-gynecomastia, impotence and frigidity. During treatment with sulpiride, increased sweating and weight gain may occur.

From the digestive system: increased activity of liver enzymes.

From the central nervous system: sedation, drowsiness, dizziness, tremor, early dyskinesia (spastic torticollis, oculogyric crises, trismus), which passes when prescribing an anticholinergic antiparkinsonian agent, rarely – extrapyramidal syndrome and related disorders (akinesia, sometimes combined with muscle hypertonicity and partially eliminated when prescribing anticholinergic antiparkinsonian agents, hyperkinesia-hypertonicity, motor arousal, akatasia). There have been cases of tardive dyskinesia characterized by involuntary rhythmic movements, mainly of the tongue and / or face, during prolonged courses of treatment, which can be observed during courses of treatment with all neuroleptics: the use of antiparkinsonian drugs is ineffective or may cause worsening of symptoms. If hyperthermia develops, the drug should be discontinued, since an increase in body temperature may indicate the development of neuroleptic malignant syndrome (NMS).

From the cardiovascular system: tachycardia, possible increase or decrease in blood pressure, in rare cases it is possible to develop orthostatic hypotension, prolongation of the QT interval, very rare cases of “torsade depointes”syndrome.

Allergic reactions: possible skin rash.

Interaction

Weakens the effect of levodopa, increases the severity of lowering blood pressure against the background of antihypertensive drugs; incompatible with alcohol and other drugs that depress the central nervous system (mutual strengthening of sedative properties).

How to take, course of use and dosage

Usually, treatment begins with intramuscular injections at a dose of 400-800 mg per day and continues for 2 weeks. The goal of therapy is to achieve the minimum effective dose.

Depending on the clinical picture of the disease, intramuscular injections of sulpiride are prescribed 1-3 times a day, which can quickly mitigate or stop the symptoms. As soon as the patient’s condition allows, you should start taking the drug inside. The course of treatment is determined by the doctor.

Special instructions

Neuroleptic malignant syndrome: if hyperthermia of undiagnosed origin develops, Eglonyl should be discontinued, as this may be one of the signs of the malignant syndrome described with the use of neuroleptics (pallor, hyperthermia, autonomic dysfunction, impaired consciousness, muscle rigidity).

Signs of autonomic dysfunction, such as increased sweating and high blood pressure, may precede the onset of hyperthermia and, therefore, represent early warning signs.

Although this effect of antipsychotics may have an idiosyncratic origin, it seems that some risk factors may predispose to it, such as dehydration or organic brain damage.

Prolongation of the QT interval: sulpiride prolongs the QT interval depending on the dose. This effect, which is known to increase the risk of developing a serious ventricular arrhythmia, such as torsade de pointes, is more pronounced in the presence of bradycardia, hypokalemia, or congenital or acquired prolonged QT interval (combination with a drug that causes prolongation of the QT interval).

If the clinical situation allows, it is recommended to make sure that there are no factors that can contribute to the development of this type of arrhythmia before prescribing Eglonyl: – bradycardia with the number of strikes is less than 55 beats/min, hypokalemia, congenital prolongation of the QT interval, simultaneous treatment with the drug, can cause severe bradycardia (less than 55 beats/min), hypokalemia, slowing of intracardiac conduction, or prolongation of the interval QT.

Except in cases of urgent intervention, patients who require treatment with antipsychotics, it is recommended in the evaluation process status to conduct ECG.

Except in exceptional cases, this drug should not be used in patients suffering from Parkinson’s disease.

In patients with impaired renal function, reduced doses should be used and control should be increased; for severe forms of renal failure, intermittent treatment is recommended.

Monitoring of Eglonyl treatment should be strengthened: – in patients with epilepsy, as the seizure threshold may be lowered;- in the treatment of elderly patients who show greater sensitivity to postural hypotension, sedation and extrapyramidal effects.

Alcohol consumption or the use of drugs containing ethyl alcohol during treatment with the drug is strictly prohibited.

During Eglonyl treatment, driving vehicles and working with mechanisms that require increased attention, as well as taking alcohol, are prohibited.

Form of production

Solution for intramuscular use

Storage conditions

At a temperature not exceeding 30 °C.

Shelf

life is 3 years.

Active ingredient

Sulpiride

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Purpose

Children over 14 years of age, Adults as prescribed by a doctor, Pregnant women as prescribed by a doctor, Children as prescribed by a doctor

Indications

Depression, Meniere’s disease, Schizophrenia, Irritable Bowel syndrome, Concussion and other traumatic brain injuries, Stomach and Duodenal Ulcers, Hangovers, Mental disorders, Manic-Depressive Psychosis, Alcoholism, Migraines, Colitis